Australian Clinical Labs LtdASX: ACL

On Market Share Buy Back

· Issued by Australian Clinical Labs Ltd

Filed with ASX · · 1 page · English

Summary by 6ix AI

The buy-back does not require shareholder approval as it falls within the limits set by the Corporations Act. The Board believes this program will enhance shareholder value while maintaining a strong balance sheet. The timing and total amount of shares purchased will depend on market conditions and the Board's assessment of capital management.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Australian Clinical Labs Ltd on 6ix

Story so far

Earlier from Australian Clinical Labs

Later from Australian Clinical Labs

All Australian Clinical Labs news releases